May 8 |
Inozyme Pharma to Participate at the Bank of America Securities 2024 Health Care Conference
|
May 8 |
Inozyme Pharma GAAP EPS of -$0.38 beats by $0.02
|
May 7 |
Inozyme Pharma Reports First Quarter 2024 Financial Results and Provides Business Highlights
|
May 3 |
Inozyme Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
Apr 9 |
Why Tilray Brands Shares Are Trading Lower By Around 22%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
|
Apr 8 |
Inozyme Pharma Announces Positive Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency (PXE) and ENPP1 Deficiency
|
Apr 2 |
Inozyme Pharma to Participate at the 23rd Annual Needham Virtual Healthcare Conference
|
Mar 28 |
Top 5 Health Care Stocks That May Plunge In March
|
Mar 26 |
Inozyme Pharma to Report Topline Data from Ongoing Phase 1/2 Trials of INZ-701 in Adults with ABCC6 Deficiency and ENPP1 Deficiency on April 8, 2024
|
Mar 12 |
Inozyme Pharma: Q4 Earnings Insights
|